This statistic shows the rate of mortality to testicular cancer incidence in England in 2016, by region. Testicular cancer occurs when cells in the testis begin to grow abnormally. In this year in the the north east of England 3 percent of males who were diagnosed died as a result of testicular cancer, this was the highest recorded rate in England. The region with the lowest rate of mortality to testicular cancer incidence was the east of England and London at 1 percent.

Dataset Description This dataset contains information on cancer deaths by country, type, and year. It includes data on 18 different types of cancer, including liver cancer, kidney cancer, larynx cancer, breast cancer, thyroid cancer, stomach cancer, bladder cancer, uterine cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, testicular cancer, nasopharynx cancer, other pharynx cancer, colon and rectum cancer, non-melanoma skin cancer, lip and oral cavity cancer, brain and nervous system cancer, tracheal, bronchus, and lung cancer, gallbladder and biliary tract cancer, malignant skin melanoma, leukemia, Hodgkin lymphoma, multiple myeloma, and other cancers.

Data Fields The dataset includes the following data fields:

• Country: The country where the cancer death occurred.
• Code: The country code for the country where the cancer death occurred.
• Year: The year in which the cancer death occurred.
• Liver cancer: The number of cancer deaths from liver cancer in the country in the year.
• Kidney cancer: The number of cancer deaths from kidney cancer in the country in the year.
• Larynx cancer: The number of cancer deaths from larynx cancer in the country in the year.
• Breast cancer: The number of cancer deaths from breast cancer in the country in the year.
• Thyroid cancer: The number of cancer deaths from thyroid cancer in the country in the year.
• Stomach cancer: The number of cancer deaths from stomach cancer in the country in the year.
• Bladder cancer: The number of cancer deaths from bladder cancer in the country in the year.
• Uterine cancer: The number of cancer deaths from uterine cancer in the country in the year.
• Ovarian cancer: The number of cancer deaths from ovarian cancer in the country in the year.
• Cervical cancer: The number of cancer deaths from cervical cancer in the country in the year.
• Prostate cancer: The number of cancer deaths from prostate cancer in the country in the year.
• Pancreatic cancer: The number of cancer deaths from pancreatic cancer in the country in the year.
• Esophageal cancer: The number of cancer deaths from esophageal cancer in the country in the year.
• Testicular cancer: The number of cancer deaths from testicular cancer in the country in the year.
• Nasopharynx cancer: The number of cancer deaths from nasopharynx cancer in the country in the year.
• Other pharynx cancer: The number of cancer deaths from other pharynx cancer in the country in the year.
• Colon and rectum cancer: The number of cancer deaths from colon and rectum cancer in the country in the year.
• Non-melanoma skin cancer: The number of cancer deaths from non-melanoma skin cancer in the country in the year.
• Lip and oral cavity cancer: The number of cancer deaths from lip and oral cavity cancer in the country in the year.
• Brain and nervous system cancer: The number of cancer deaths from brain and nervous system cancer in the country in the year.
• Tracheal, bronchus, and lung cancer: The number of cancer deaths from tracheal, bronchus, and lung cancer in the country in the year.
• Gallbladder and biliary tract cancer: The number of cancer deaths from gallbladder and biliary tract cancer in the country in the year.
• Malignant skin melanoma: The number of cancer deaths from malignant skin melanoma in the country in the year.
• Leukemia: The number of cancer deaths from leukemia in the country in the year.
• Hodgkin lymphoma: The number of cancer deaths from Hodgkin lymphoma in the country in the year.
• Multiple myeloma: The number of cancer deaths from multiple myeloma in the country in the year.
• Other cancers: The number of cancer deaths from other cancers in the country in the year.

Data Source The data in this dataset was collected from the World Health Organization (WHO). The WHO collects data on cancer deaths from countries around the world.

Usage This dataset can be used to study cancer deaths by country, type, and year. It can also be used to compare cancer death rates between different countries or over time.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16169071%2F98f6c6f321aad496b703685519b6df6a%2Fcancer-cells-th.jpg?generation=1694610742970317&alt=media" alt="">

In Germany, the number of deaths caused by testicular cancer had an overall increase between 2019 and 2023, with *** men dying from this cancer type in 2023, compared to *** deaths in 2019. This statistic depicts the number of testicular cancer deaths in Germany between 2019 and 2023.

This statistic shows the registrations of newly diagnosed cases of testicular cancer in England in 2022, by age group. In this year, *** cases were registered among 30 to 34 year olds.

In 2021, 6.9 males per 100,000 population in England were registered as newly diagnosed with testicular cancer. This was a slight decrease from the previous year's rate of registration. This statistic shows the rate of newly diagnosed cases of testicular cancer per 100,000 population in England from 1995 to 2022.

BackgroundThe incidence rate of testicular cancer has risen in many countries during recent decades. This study aimed to outline the impact of testicular cancer on the Middle East and North Africa (MENA) region from 1990 to 2019, examining its burden by age group and according to the socio-demographic index (SDI).MethodsData on the incidence, death, and disability-adjusted life-years (DALYs) due to testicular cancer were retrieved from the Global Burden of Disease study 2019. The counts and age-standardized rates (per 100,000) were reported, and all rates were accompanied by 95% uncertainty intervals (UIs).ResultsIn MENA, the age-standardized incidence rate of testicular cancer was 1.4 per 100,000 in 2019, showing a 244.0% increase since 1990. Similarly, the annual death rate, at 0.1, experienced a 2.6% rise during the same period. In 2019, testicular cancer accounted for 31.1 thousand DALYs, marking an age-standardized rate of 5.0, which was 2.8% higher than in 1990. The 1-4 age group exhibited the largest incidence rate in 2019. In addition, in both 1990 and 2019 the MENA/Global DALY ratio was higher than one in the 1-14 year age groups. During the period 1990 to 2019, the age-standardized DALY rate of testicular cancer steadily rose with higher SDI values, except for a decrease observed at an SDI of 0.8.ConclusionOver the last thirty years, there has been a notable rise in the burden of testicular cancer in the MENA region.

Financial overview and grant giving statistics of Testicular Cancer Resource Center

Results of the unadjusted cancer cluster analysis of testicular cancer in Denmark. There were k = 15 nearest neighbors used in every analysis. The number of significant clusters, number of persons in the largest cluster, indication of whether there were significant global statistics, the location of each cluster, and whether there were individual cases which were found in clusters using each control group are listed for each analysis. All testicular cancer cases, seminomas only, and the mothers of cases were aligned according to age at diagnosis, calendar year of diagnosis, and number of years prior to diagnosis (YPD). For the two largest clusters, the timing of the clusters is indicated.Unadjusted Analysis.

IntroductionSociodemographic disparities in genitourinary cancer-related mortality have been insufficiently studied, particularly across multiple cancer types. This study aimed to investigate gender, racial, and geographic disparities in mortality rates for the most common genitourinary cancers in the United States.MethodsMortality data for prostate, bladder, kidney, and testicular cancers were obtained from the Centers for Disease Control and Prevention (CDC) WONDER database between 1999 and 2020. Age-adjusted mortality rates (AAMRs) were analyzed by year, gender, race, urban–rural status, and geographic region using a significance level of p < 0.05.ResultsOverall, AAMRs for prostate, bladder, and kidney cancer declined significantly, while testicular cancer-related mortality remained stable. Bladder and kidney cancer AAMRs were 3–4 times higher in males than females. Prostate cancer mortality was highest in black individuals/African Americans and began increasing after 2015. Bladder cancer mortality decreased significantly in White individuals, Black individuals, African Americans, and Asians/Pacific Islanders but remained stable in American Indian/Alaska Natives. Kidney cancer-related mortality was highest in White individuals but declined significantly in other races. Testicular cancer mortality increased significantly in White individuals but remained stable in Black individuals and African Americans. Genitourinary cancer mortality decreased in metropolitan areas but either increased (bladder and testicular cancer) or remained stable (kidney cancer) in non-metropolitan areas. Prostate and kidney cancer mortality was highest in the Midwest, bladder cancer in the South, and testicular cancer in the West.DiscussionSignificant sociodemographic disparities exist in the mortality trends of genitourinary cancers in the United States. These findings highlight the need for targeted interventions and further research to address these disparities and improve outcomes for all populations affected by genitourinary cancers.

Financial overview and grant giving statistics of Testicular Cancer Foundation

From 2014 to 2020, the chances that a male in the U.S. diagnosed with prostate cancer would survive the first five years after diagnosis was 97 percent. This statistic shows the five-year relative survival rates for prostate and testicular cancer in the U.S. from 1975 to 2020.

BackgroundTesticular germ cell tumor (TGCT) patients and survivors have excess mortality compared to the general male population, but relative survival (RS) has been scarcely studied. We investigated causes of excess mortality and their impact on RS among men diagnosed with TGCT in Norway, 1953–2015.Methods and findingsUsing registry data (n = 9541), standardized mortality ratios (SMRs) and RS were calculated. By December 31st, 2015, 816 testicular cancer (TC) and 1508 non-TC deaths had occurred (non-TC SMR: 1.36). Within five years of TGCT diagnosis, 80% were TC deaths. Non-TC second cancer (SC) caused 65% of excess non-TC deaths, of which 34% from gastric, pancreatic or bladder cancer. SC SMRs remained elevated ≥26 years of follow-up. In localized TGCT diagnosed >1979, SC SMRs were only elevated after seminoma. Cardiovascular disease caused 9% and other causes 26% of excess non-TC deaths, of which 58% from gastrointestinal and genitourinary disorders. RS continuously declined with follow-up. TGCT patients diagnosed >1989 had superior five-year TC-specific RS (98.3%), lower non-TC SMR (1.21), but elevated SMRs for several SCs, infections, Alzheimer’s disease, genitourinary disease and suicide. A limitation was lack of individual treatment data.ConclusionsRS declines mainly from TC deaths <5 years after TGCT diagnosis. Later, excess SC mortality becomes particularly important, reducing RS even ≥26 years. Radiotherapy; standard adjuvant seminoma treatment 1980–2007, is likely an important contributor, as are chemotherapy and possibly innate susceptibilities. Vigilant long-term follow-up, including psychosocial aspects, is important. Further research should focus on identifying survivor risk groups and optimizing treatment.

This statistic shows the rate of registrations of newly diagnosed cases of testicular cancer per 100,000 population in England in 2020, by region. With a rate of approximately eight newly diagnosed males with testicular cancer per 100,000 population in 2020, the region most affected by testicular cancer was the East.

The Get Data Out programme from the National Disease Registration Service publishes detailed statistics about small groups of cancer patients in a way that ensures patient anonymity is maintained. The Get Data Out programme currently covers 15 cancer sites. This data release is a corrected re-release of detailed statistics for 2013-2019 treatment data. The correction means that surgery counts are no longer slightly underreported. There are some small changes in group sizes of usually no more than 2%, although this is larger for non-melanoma skin cancers. The 15 cancer sites now covered by Get Data Out are: ‘Bladder, Urethra, Renal Pelvis and Ureter’, ‘Bone cancer’, ‘Brain, meningeal and other primary CNS tumours’, ‘Eye cancer’, ‘Head and neck’, ‘Kaposi sarcoma’, ‘Kidney’, ‘Oesophageal and Stomach’, ‘Ovary, fallopian tube and primary peritoneal carcinomas’, ‘Pancreas’, ‘Prostate’, ‘Sarcoma’, ‘Skin tumours’, ‘Soft tissue and peripheral nerve cancer’, ‘Testicular tumours including post-pubertal teratomas’. Anonymisation standards are designed into the data by aggregation at the outset. Patients diagnosed with a certain type of tumour are divided into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These groups are aimed to be clinically meaningful and differ across cancer sites. For each group of patients, Get Data Out routinely publish statistics about incidence, routes to diagnosis, treatments and survival. All releases and documentation are available on the Get Data Out main technical page. Before using the data, we recommend that you read the guide for first time users. The data is available in an open format for anyone to access and use. We hope that by releasing anonymous detailed data like this we can help researchers, the public and patients themselves discover more about cancer. If you have feedback or any other queries about Get Data Out, please email us at NDRSenquires@nhs.net and mention 'Get Data Out' in your email.

ObjectivesTo quantify the burden and variation trends of cancers in children under 5 years at the global, regional, and national levels from 1990 to 2019.MethodsEpidemiological data for children under 5 years who were diagnosed with any one childhood cancer were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) from 1990 to 2019. The outcomes were the absolute numbers and rates of incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) for different types of cancer.ResultsIn 2019, 8,774,979.1 incident cases (95% uncertainty interval [UI]: 6,243,599.2 to11,737,568.5) and 8,956,583.8 (6,446,323.9 to 12,364,520.8) prevalent cases of cancer in children under 5 years were identified worldwide; these cancers resulted in 44,451.6 (36,198.7 to 53,905.9) deaths and 3,918,014.8 (3,196,454.9 to 4,751,304.2) DALYs. From 1990 to 2019, although the numbers of incident and prevalent cases only decreased by −4.6% (−7.0 to −2.2) and −8.3% (−12.6 to −3.4), respectively, the numbers of deaths and DALYs clearly declined by −47.8% (−60.7 to −26.4) and −47.7% (−60.7 to −26.2), respectively. In 2019, the middle sociodemographic index (SDI) regions had the highest incidence and prevalence, whereas the low SDI regions had the most mortality and DALYs. Although all of the SDI regions displayed a steady drop in deaths and DALYs between 1990 and 2019, the low-middle and low SDI regions showed increasing trends of incidence and prevalence. Leukemia remained the most common cancer globally in 2019. From 1990 to 2019, the burdens of leukemia, liver cancer, and Hodgkin's lymphoma declined, whereas the incidence and prevalence of other cancers grew, particularly testicular cancer.ConclusionsThe global childhood cancer burden in young children has been steadily decreasing over the past three decades. However, the burdens and other characteristics have varied across different regions and types of cancers. This highlights the need to reorient current treatment strategies and establish effective prevention methods to reduce the global burden of childhood cancer.

The Molecular Diagnosis of Testicular Cancer market is a vital segment of the healthcare industry that focuses on the advanced methods used for the identification and treatment of testicular cancer at a molecular level. Testicular cancer is one of the most common malignancies among young men, making early and accura

BackgroundThe incidence of kidney, bladder, and prostate cancer ranked ninth, sixth, and third in male cancers respectively, meanwhile, the incidence of testicular cancer also increased gradually in the past 30 years.ObjectiveTo study and present estimates of the incidence, mortality, and disability of kidney, bladder, prostate, and testicular cancer by location and age from 1990 to 2019 and reveal the mortality risk factors of them.MaterialsThe Global Burden of Diseases Study 2019 was used to obtain data for this research. The prediction of cancer mortality and incidence was based on mortality-to-incidence ratios (MIRs). The MIR data was processed by logistic regression and adjusted by Gaussian process regression. The association between the socio-demographic index and the incidence or disease burden was determined by Spearman's rank order correlation.ResultsGlobally in 2019, there were 371,700 kidney cancer cases with an age-standardized incidence rate (ASIR) of 4.6 per 100,000, 524,300 bladder cancer cases, with an ASIR of 6.5 per 100,000, 1,410,500 prostate cancer cases with an ASIR of 4.6 per 100,000 and 109,300 testicular cancer incident cases with an ASIR of 1.4 per 100,000, the ASIR of these four cancers increased by 29.1, 4, 22, and 45.5% respectively. The incidence rate of the four cancers and the burden of kidney cancer were positively correlated with the socio-demographic index (SDI), regions with a higher SDI faced more of a burden attributable to these four cancers. High body-mass index has surpassed smoking to be the leading risk factor in the past thirty years for kidney cancer mortality. Smoking remained the leading risk factor for cancer-related mortality for bladder cancer and prostate cancer and the only risk factor for prostate cancer. However, the contribution of high fasting plasma glucose to bladder cancer mortality has been increasing.ConclusionThe incidence of bladder, kidney, prostate, and testicular cancer is ever-increasing. High-income regions face a greater burden attributable to the four cancers. In addition to smoking, metabolic risk factors may need more attention.

In Germany, the number of testicular cancer cases remained fairly constant between 2019 and 2022, with ***** men diagnosed with this cancer in 2022. This statistic depicts the number of testicular cancer cases in Germany between 2019 and 2022.

As of 2024, more than ******* men were living with a diagnosis of prostate or testicular cancer in Italy. Among them, the majority had a diagnosis of prostate cancer, with ******* cases. The graph presented shows the number of people living with a diagnosis of prostate and testicular cancer in Italy as of 2024.

Antitumor Antibiotics Market Outlook

The global antitumor antibiotics market size was valued at approximately USD 2.8 billion in 2023 and is projected to reach around USD 4.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.2% over the forecast period. This steady market growth can be attributed to the increasing prevalence of various cancers, advancements in drug formulations, and growing awareness about cancer treatments.

One of the primary growth factors for the antitumor antibiotics market is the rising incidence of cancer globally. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with millions of new cases diagnosed each year. The growing prevalence of cancer has necessitated the development of effective treatment options, thereby driving demand for antitumor antibiotics. Additionally, advancements in medical technology and pharmaceutical research are continuously enhancing the efficacy and safety profiles of these drugs, further boosting market growth.

Another critical factor contributing to market expansion is the increasing investment in oncology research and development. Pharmaceutical companies and research institutions are actively investing in the discovery of novel antitumor antibiotics with improved therapeutic outcomes. Government initiatives and funding for cancer research are also playing a significant role in accelerating the development of new drugs. These investments not only facilitate the introduction of innovative treatments but also improve the accessibility and affordability of cancer therapies, thereby contributing to market growth.

Furthermore, the growing awareness about cancer and its treatment options is driving the demand for antitumor antibiotics. Public health campaigns, educational programs, and media coverage have significantly increased awareness about the importance of early diagnosis and treatment of cancer. As a result, more patients are seeking medical attention at an early stage, leading to higher demand for effective cancer therapies, including antitumor antibiotics. Additionally, the increasing availability of diagnostic facilities and cancer screening programs is aiding in the early detection of cancer, further propelling market growth.

Drug Type Analysis

The antitumor antibiotics market by drug type is segmented into anthracyclines, mitomycin-C, bleomycin, dactinomycin, and others. Among these, anthracyclines hold a significant market share due to their widespread use and proven efficacy in treating various types of cancer. Anthracyclines, such as doxorubicin and daunorubicin, are known for their potent antineoplastic activity, making them a preferred choice in chemotherapy regimens. The extensive clinical use and ongoing research to improve their therapeutic index further solidify their position in the market.

Bleomycin, a vital component in the arsenal of antitumor antibiotics, has been instrumental in the treatment of various cancers, including Hodgkin's lymphoma, testicular cancer, and cervical cancer. Its unique mechanism of inducing DNA strand breaks distinguishes it from other chemotherapeutic agents, making it a valuable option in combination chemotherapy protocols. Despite the potential for pulmonary toxicity, ongoing research is focused on optimizing dosing regimens to mitigate adverse effects while preserving its therapeutic efficacy. The continued use of Bleomycin in specific cancer types underscores its importance in the oncology field, ensuring its sustained market presence.

Mitomycin-C is another crucial segment within the antitumor antibiotics market. This drug is primarily used in the treatment of stomach, pancreas, and colon cancers. Its mechanism of action involves cross-linking DNA, which inhibits DNA synthesis and leads to cell death. The effectiveness of mitomycin-C in combination with other chemotherapeutic agents has been well-documented, contributing to its steady demand in the oncology field. Additionally, ongoing research to enhance its delivery and reduce side effects is expected to drive market growth.

Bleomycin, known for its application in treating Hodgkin's lymphoma, testicular cancer, and cervical cancer, also holds a notable market share. The unique mechanism of action of bleomycin, which involves inducing DNA strand breaks, makes it a valuable component of combination chemotherapy protocols. Despite concerns about pulmonary toxicity, the clinic